We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Biomarker Discovered for Uterine Cancer

By LabMedica International staff writers
Posted on 05 May 2015
A new biomarker has been discovered which makes it possible to identify women with uterine cancer who have a high risk of recurrence.

Endometrial cancer of the uterus is the most common form of gynecologic cancer in Europe and North America and the treatment primarily consists of removing the uterus and in some cases offering chemotherapy if the risk of recurrence is deemed high. More...


Scientists at Uppsala University (Sweden) and their colleagues conducted a study based on samples collected from 500 women who were diagnosed with uterine cancer between the years 1981 and 2007. Tissue microarrays (TMA) were constructed from formalin-fixed, paraffin-embedded (FFPE) primary tumors derived from hysterectomy specimens. Duplicate 1.0 mm diameter cores from each donor block were assembled into a recipient TMA block using the Beecher Manual Tissue Arrayer MTA-1 (Estigen OÜ; Tartu, Estonia).

Automated immunohistochemistry (IHC) was performed using a LabVision Autostainer 480S (Thermo Fisher Scientific; Runcorn, UK). Stained slides were scanned using an Aperio ScanScope XT Slide Scanner (Aperio Technologies; Vista, CA, USA). The l-asparaginase (ASRGL1) protein was identified as an endometrial carcinoma biomarker candidate. ASRGL1 expression was immunohistochemically evaluated. The protein ASRGL1 is an enzyme that normally exists in healthy cells of the uterus.

The investigators found that patients who had entirely or partially lost ASRGL1 in the tumor cells had a much higher risk of the cancer recurring and dying from the disease, while patients with sustained high levels of ASRGL1 had a much lower risk of recurrence. The study also shows that ASRGL1 is an independent prognostic factor, even after compensating for other risk factors such as tumor stage and tumor grade.

Per-Henrik Edqvist, PhD, the lead author of the study, said, “'I view the results as a first step towards personal treatment of uterine cancer. Today, 10% to 15% of the patients suffer recurrences, even though they were considered low risk patients according to classic diagnostics. By using ASRGL1, the chance of identifying such hidden high-risk patients and offer them more aggressive treatment after their operation increases.” The study was published on April 6, 2015, in the journal Gynecologic Oncology.

Related Links:

Uppsala University
Estigen
Thermo Fisher Scientific
Aperio Technologies



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Host Response Immunoassay Test
MeMed BV
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The discovery of early markers for ovarian cancer that would have improved sensitivity could aid detection (Photo courtesy of Adobe Stock)

Highly Accurate Biomarkers Could Detect Ovarian Cancer Before Clinical Diagnosis

Ovarian cancer is a deadly and challenging disease, primarily because early detection is difficult. Most women (70-75%) are diagnosed only after the cancer has already spread, which significantly reduces... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.